A case of seizures 1 week after the cessation of interferon-α therapy

Psychiatry and Clinical Neurosciences

Volumn 53, Issue 3, 1999, Pages 417-420

  Seno, Haruo ^a   Inagaki, Takuji ^a   Itoga, Motoi ^a   Miyaoka, Tsuyoshi ^a   Ishino, Hiroshi ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Interferon therapy; Electroencephalogram abnormality; Seizures

Indexed keywords

ALPHA INTERFERON; CARBAMAZEPINE; LITHIUM CARBONATE; MAPROTILINE; PHENOBARBITAL; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; DELIRIUM; DEPRESSION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEMALE; GRAND MAL SEIZURE; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LEUKOPENIA; MANIC DEPRESSIVE PSYCHOSIS; ORAL DRUG ADMINISTRATION; TONIC CLONIC SEIZURE;

DELIRIUM; DELTA RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; EPILEPSY, TONIC-CLONIC; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-ALPHA; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032856226     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.1999.00566.x     Document Type: Article

References (16)

1. Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf. 1994; 10: 281-291.
2. Merimsky O, Chaitchik S. Neurotoxicity of interferon-α. Anticancer Drugs 1992; 3: 567-570.
3. Mattson K, Niiranen A, Iivanainen M et al. Neurotoxicity of interferon. Cancer Treat. Rep. 1982; 67: 958-961.
4. Janssen HLA, Berk L, Vermeulen M, Schalm SW. Seizures associated with low-dose α-interferon. Lancet 1990; 336: 1580.
5. Yamada Y, Sawada Y, Kawakami J, Nakamura K, Iga T. Drug-induced neuropsychiatric disorders: interferon-α and seizures. Yakkyoku 1991; 42: 91-97 (in Japanese).
6. Meters CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672-676.
7. Otsubo T, Miyaoka H, Kamijima K, Okuni M, Ishii M, Mitamura K. Depression during interferon therapy in chronic hepatitis C patients: A prospective study. Psychiat. Neurol. Japn. 1997; 99: 101-127 (in Japanese).
8. Nozaki O, Takagi C, Takaoka K, Takata T, Yoshida M. Psychiatric manifestations accompanying interferon therapy for, patients with chronic hepatitis C. An overview of cases in Japan. Psychiatr. Clin. Nenrosci. 1997; 51: 175-180.
9. Baldessarini RJ, Stephens JH. Lithium carbonate for affective disorder: I. Clinical pharmacology and toxicology. Arch. Gen. Psychiatry 1970; 22: 72-77.
10. Demers R, Lukesh R, Prichard J. Convulsion during lithium therapy. Lancet 1970; ii: 315-316.
11. Dessain EC, Schatzberg AF, Woods BT, Cole JO. Maprotiline treatment in depression: A perspective on seizures. Arch. Gen. Psychiatry 1986; 43: 86-90.
12. Greig NH, Soncrant TT, Wozniak KM, Rapoport SI. Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration. J. Phamacol. Exp. Ther. 1988; 245: 574-580.
13. Krueger JM, Dinarello CA, Shoham S, Davenne D, Walter J, Kubillus S. Interferon alpha-2 enhances slow-wave sleep in rabbits. Int. J. Immunopharmacol. 1987; 9: 23-30.
14. Kuriyama K, Hori T, Mori T, Nakashima T. Actions of interferon alpha and interleukin-1 beta on the glucose-responsive neurons in the ventromedial hypothalamus. Brain Res. Bull. 1990; 24: 803-810.
15. De Sarro GB, Masuda Y, Ascioti C, Audino MG, Nistico G. Behavioral and ECG spectrum changes induced by intracerebral infusion of interferons and interleukin-2 in rats are antagonized by naloxane. Neuropharmacology 1990; 29: 167-179.
16. Bender CM, Monti EJ, Kerr ME. Potential mechanisms of interferon neurotoxicity. Cancer Prac. 1996; 4: 35-39.